全部树

Cost of living data for global residentsNEW

China high-tech enterprise patent statisticsNEW

Statistics on entry and exit information of Chinese partnershipsNEW

Patents and citation data of Little Giant and individual champion companiesNEW

Small giant and single champion enterprise design patent details table

Digital economy patent application and authorization dataNEW

Tax investigation of corporate patents and citation dataNEW

Patent and citation data of Chinese industrial enterprisesNEW

Patent and citation data of A-share listed companiesNEW

Patent details of A-share listed companies
A-share listed companies' design patent application details table
Details of Design Patents Authorized by A-share Listed Companies

Statistics on the entry and exit of Chinese industrial and commercial enterprisesNEW

Basic information data of manufacturing industrial and commercial registered enterprisesNEW

China foreign trade index data

China university patent statisticsNEW

Green patents and citation data of Chinese industrial enterprisesNEW

Details of Green Patents of Chinese Industrial Enterprises

Green patents and citation data of A-share listed companies

A-share listed companies green patent details table

  The 2019 Novel Coronavirus (2019-nCoV), discovered through viral pneumonia cases in Wuhan in 2019, was officially named by the World Health Organization (WHO) on January 12, 2020. Coronaviruses constitute a large family of viruses known to cause illnesses ranging from common colds to more severe diseases such as Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The novel coronavirus represents a new strain previously unidentified in humans.

  On January 21, 2020, the National Health Commission issued Announcement No. 1, classifying pneumonia caused by the novel coronavirus as a Category B infectious disease under the Law of the People's Republic of China on the Prevention and Treatment of Infectious Diseases, while implementing preventive and control measures typically applied to Category A infectious diseases. After eighteen months since the initial large-scale outbreak, the Chinese government has accumulated substantial experience in epidemic prevention. However, the pandemic persists, with ongoing efforts to combat the virus across China and globally. During the early stages of detection, China rapidly isolated the novel coronavirus, completed whole-genome sequencing, developed nucleic acid detection kits, and received WHO recognition for its sequencing speed. Although no specific treatment exists for COVID-19, many symptoms can be managed through clinical interventions, and vaccine/therapeutic development remains under intensive research.

  The CnOpenData platform has organized standardized data related to COVID-19 prevention, encompassing global standards for medical protective products (医用防护产品), infectious disease testing (传染病检验检测), and medical infrastructure (医用基础设施). This database provides standardized information support for pandemic-related research, treatment, and protection efforts, aiming to optimize resource utilization and enhance scientific prevention/medical interventions.

  To support medical research and public health initiatives, CnOpenData has opened access to COVID-19 prevention standard data for scholars and the public (contact customer service for access). We remain committed to advancing the global fight against the pandemic.


Field Specifications


Data Structure

医用基础设施传染病医院建设装配式建筑标准药物性废物化学性废物传染病检验检测法定传染病检测其他传染病检测口岸卫生检疫医用防护产品口罩防护服护目镜手套消毒剂新冠病毒防疫标准信息数据

Sample Data

Complete List of Medical Protective Products

Complete List of Medical Infrastructure

Port Health Quarantine Records


Data Update Frequency

Annual Update